Dr Reddy's Q4 PAT may rise 28% YoY; margins likely to fall, say analysts

The pharmaceutical giant may witness some impact due to its large exposure of the business to Russia, and CIS regions.

Hyderabad-based drugmaker Dr Reddy’s Laboratories is set to announce results for the fourth quarter of FY22 (Q4FY22) on Thursday, May 19. Analysts expect the company to post revenue growth of 8-16 per cent in Q4FY22 on the back of decent sales across all geographies and a ramp-up in volumes of its Vascepa generic in the US.

The company’s net profit is expected to rise 28 per cent year-on-year (YoY), as per an average of estimates by four brokerages.
 

However, on a quarterly basis, it may register a decline in net profits due to cost pressures that may have also likely